Introduction —
This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately:
●(See "Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders".)
●(See "Society guideline links: von Willebrand disease".)
●(See "Society guideline links: Rare inherited bleeding disorders".)
●(See "Society guideline links: Acquired bleeding disorders".)
International
●European Hematology Association (EHA)-International Society on Thrombosis and Haemostasis (ISTH)-European Association for Hemophilia and Allied Disorders (EAHAD)-European Stroke Organization (ESO): Clinical practice guidance document on use of antithrombotic therapy in patients with hemophilia – A selected synopsis (2025)
•EHA-ISTH-EAHAD-ESO: Clinical practice guidance for antithrombotic treatment in patients with hemophilia (2023)
●ISTH: Clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology (2024)
●ISTH Scientific and Standardization Committee (SSC) Working Group on Gene Therapy: Recommendations for a minimum data set for monitoring gene therapy in hemophilia (2024)
●SSC of the ISTH: Recommendations and guidelines on a new hemophilia carrier nomenclature to define hemophilia in women and girls (2021)
●World Federation of Hemophilia (WFH): Guidelines for the management of hemophilia, 3rd edition (2020)
●SSC of the ISTH: Recommendations and guidelines on the definition, diagnosis, and management of mild hemophilia A (2018)
●SSC of the ISTH: Recommendations and guidelines on the predictive value of factor VIII/factor IX levels to define the severity of hemophilia (2018)
●SSC of the ISTH: Recommendations and guidelines on when and how to start prophylaxis in boys with severe hemophilia without inhibitors (2016)
●SSC of the ISTH: Recommendations and guidelines on definitions in hemophilia (2014)
Canada
●National Bleeding Disorders Foundation (NBDF)-McMaster University: Guideline on care models for haemophilia management (2016)
United States
●National Bleeding Disorders Foundation (NBDF): Medical and Scientific Advisory Council (MASAC) recommendations concerning products licensed for the treatment of hemophilia and selected disorders of the coagulation system (2024)
●NBDF: MASAC recommendations for physical therapy management for bone health in people with bleeding disorders (2024)
●NBDF: MASAC recommendations for physical therapy management for people with bleeding disorders and chronic pain (2024)
●NBDF: MASAC recommendations on increasing access to mental health and substance use disorder treatment facilities and programs for persons with bleeding disorders (2024)
●NBDF: MASAC recommendations regarding diagnosis and management of inherited bleeding disorders in girls and women with personal and family history of bleeding (2024)
●NBDF: MASAC recommendation regarding the need for bleeding disorders gene therapy lexicon development (2024)
●NBDF: MASAC recommendations on administration of vaccines to individuals with bleeding disorders (2023)
●NBDF: MASAC recommendations on hemophilia treatment center preparedness for delivering gene therapy for hemophilia (2023)
●NBDF: MASAC recommendations regarding physical therapy management for the care of persons with bleeding disorders (2023)
●NBDF: MASAC recommendation concerning prophylaxis for hemophilia A and B with and without inhibitors (2022)
●NBDF: MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with hemophilia and inhibitors (2022)
●NBDF: MASAC recommendation on the use and management of Emicizumab-kxwh (Hemlibra) for hemophilia A with and without inhibitors (2022)
●NBDF: MASAC guidelines for pregnancy and perinatal management of women with inherited bleeding disorders and carriers of hemophilia A or B (2021)
●NBDF: MASAC recommendations for bleeding prophylaxis in bleeding disorder patients undergoing GI endoscopy (2020)
●NBDF: MASAC recommendations for management of chronic pain in persons with bleeding disorders – Guidance for practical application of the Centers for Disease Control's opioid prescribing guidelines (2020)
●NBDF: MASAC guidelines for emergency department management of individuals with hemophilia and other bleeding disorders (2019)
●NBDF: MASAC recommendation for liver biopsies in gene therapy trials for hemophilia (2019)
●NBDF: MASAC recommendation on SIPPET (Survey of Inhibitors in Plasma-Product-Exposed Toddlers) – Results and recommendations for treatment products for previously untreated patients with hemophilia A (2016)
●NBDF: MASAC recommendations on treatment of hepatitis C in individuals with hemophilia and other bleeding disorders (2016)
●NBDF-McMaster University: Guideline on care models for haemophilia management (2016)
●NBDF: MASAC recommendations on standardized testing and surveillance for inhibitors in patients with hemophilia A and B (2015)
●US guidelines for immune tolerance induction in patients with haemophilia a and inhibitors (2015)
●NBDF: MASAC recommendation regarding home factor supply for emergency preparedness for patients with hemophilia and other bleeding disorders (2014)
●NBDF: MASAC recommendations on liver biopsy in individuals with hemophilia (2013)
●NBDF: MASAC recommendation regarding prophylaxis with bypassing agents in patients with hemophilia and high titer inhibitors (2013)
Europe
●European Hematology Association (EHA)-International Society on Thrombosis and Haemostasis (ISTH)-European Association for Hemophilia and Allied Disorders (EAHAD)-European Stroke Organization (ESO): Clinical practice guidance document on use of antithrombotic therapy in patients with hemophilia – A selected synopsis (2025)
•EHA-ISTH-EAHAD-ESO: Clinical practice guidance for antithrombotic treatment in patients with hemophilia (2023)
●European Society of Cardiology (ESC) and EAHAD: Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy – A clinical consensus statement (2025)
United Kingdom
●United Kingdom Haemophilia Centres Doctors' Organisation (UKHCDO) Gene Therapy Taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults (2024)
●UKHCDO: Guideline for gynaecological management of women with inherited bleeding disorders (2022)
●UKHCDO: Consensus on immune tolerance induction in severe haemophilia A, update (2021)
●British Society of Haematology (BSH): Guideline on the use of prophylactic factor replacement for children and adults with haemophilia A and B (2020)
●UKHCDO: Guideline on laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia (2019)
●UKHCDO: Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A – Combined analysis of three studies (2019)
●UKHCDO: Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders (2019)
●UKHCDO: Interim guidance for treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab (2018)
●UKHCDO and Royal College of Obstetricians and Gynaecologists (RCOG): Green-top guideline for the management of inherited bleeding disorders in pregnancy (2017)
●UKHCDO: Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia (2017)
●UKHCDO: Guidance on the dental management of patients with haemophilia and congenital bleeding disorders (2013, reviewed 2016)
●UKHCDO: Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A (2010, reviewed 2014)
●UKHCDO: Emergency and out of hours care of patients with bleeding disorders – Standards of care for assessment and treatment (2009, reviewed 2013)
●BSH: Guideline for the diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia (2012)
India
●Indian Academy of Pediatrics (IAP): Standard treatment guidelines – Hemophilia (2022)
●IAP: Consensus statement on the diagnosis and management of hemophilia (2018)
Australia–New Zealand
●Australian Haemophilia Centre Directors' Organisation (AHCDO): Guidelines for the management of haemophilia in Australia (2024)
Japan
●[In Japanese] Japanese Society on Thrombosis and Hemostasis (JSTH): Guideline for hemostatic treatment for patients with hemophilia, 2019 supplement (published 2020)
●[In Japanese] JSTH: Clinical guidelines on acquired hemophilia, revised edition (2017)
●[In Japanese] JSTH: Guidelines for hemostasis treatment for congenital hemophilia patients with inhibitors, supplement (2015)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients with inhibitors, supplement (2014)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for congenital hemophilia patients with inhibitors (revised 2013)
●[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors, supplement (2015)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors, supplement (revised 2014)
•[In Japanese] JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors (revised 2013)
